pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor
Daiichi Sankyo US
Daiichi Sankyo
NovaPharmaNews editorial coverage mentioning Daiichi Sankyo US — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
- Employees
- 4,386
- Programs
- 58
- Drugs
- 66
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Daiichi Sankyo US — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Daiichi Sankyo US — regulatory, clinical, and market analysis.
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.
EMA backs datopotamab deruxtecan for advanced lung cancer
EMA action on datopotamab deruxtecan adds a key catalyst for lung cancer tracking, even as the program’s regulatory path differs by region. For BD teams, investors, and analysts, the story now centers on approval status, label scope, and the next clinical and filing milestones.
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program’s clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop.
Merck's ADC Success: Insights from Global Trial Results
This article delves into Merck's successful antibody-drug conjugates (ADCs) and their global trial results, highlighting key insights for investors and BD teams.
FDA Approval for Datroway: Implications for Breast Cancer Treatment
The FDA has granted approval for Datroway, a significant development for breast cancer treatment by Daiichi Sankyo and AstraZeneca. This article explores the implications for investors and pharma teams.
AstraZeneca and Daiichi Secure FDA Approval for Datroway in TNBC
AstraZeneca and Daiichi have gained FDA approval for Datroway as a first-line treatment for TNBC, surpassing Gilead. This article explores the implications for the pharmaceutical landscape.